EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia

Thazha P Prakash iD, Adam E Mullick, Stan Riney, Jinghua Yu, Mehran Nikan, Clare Quirk, Amanda Crutchfield, Sagar S Damle, Stephanie Klein, Eric E Swayze

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkaf1063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Thazha P Prakash und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ionis Pharmaceuticals Inc., 2855 Gazelle Ct., Carlsbad CA 92010, United States. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hypertriglyceridemia, RNA, Small Interfering. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ionis Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apolipoprotein C-III (APOC3) plays a crucial role in triglyceride metabolism, and its high expression leads to hypertriglyceridemia, which can contribute to an increased risk of cardiovascular disease and, when severely increased, can lead to acute pancreatitis. Loss-of-function variants in APOC3 are linked to lower triglyceride levels and reduced incidence of coronary artery disease. APOC3 mRNA, primarily synthesized by hepatocytes, is an ideal target for GalNAc-conjugated RNA-targeted therapies such as the antisense oligonucleotide (ASO) oleszarsen and small-interference RNA (siRNA) plozasiran. Herein, we systematically evaluate siRNA chemical modifications or multiple siRNAs to identify a long-acting APOC3 siRNA with a minimal number of 2’-F nucleotides. Using a series of structure-activity relationship (SAR) studies, we explored the effects of various oligonucleotide chemical modification scaffolds on siRNA potency, efficacy, and durability. These efforts led to the identification of an APOC3 targeting siRNA containing a novel chemical scaffold with robust activity and an extended duration of action in preclinical models. Additionally, selectivity and tolerability assessments in human cells, rodents, and nonhuman primates showed excellent safety and tolerability. A comparative analysis of the lead APOC3 siRNA with a surrogate of a clinical-stage APOC3 siRNA drug suggests the potential for similar or better potency and efficacy combined with less frequent dosing, potentially reducing the treatment burden on patients with hypertriglyceridemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIHypertriglyceridemiaRNA, Small InterferingHumansAnimalsMiceStructure-Activity RelationshipRatsMaleTriglyceridesOligonucleotides, AntisenseHepatocytes

Substanzen

Apolipoprotein C-IIIRNA, Small InterferingAPOC3 protein, humanTriglyceridesOligonucleotides, Antisense

Autor:innen und Institutionen

  • Ionis Pharmaceuticals Inc., 2855 Gazelle Ct., Carlsbad CA 92010, United States.

ORCID-Profile: Thazha P Prakash

Förderung

  • Ionis Pharmaceuticals Inc

Zitieren

APA

Prakash, T. P., Mullick, A. E., Riney, S., Yu, J., Nikan, M., Quirk, C., Crutchfield, A., Damle, S. S., Klein, S., & Swayze, E. E. (2025). Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1063

Vancouver

Prakash TP, Mullick AE, Riney S, Yu J, Nikan M, Quirk C, et al. Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf1063

BibTeX
@article{Prakash2025,
  author = {Prakash, Thazha P and Mullick, Adam E and Riney, Stan and Yu, Jinghua and Nikan, Mehran and Quirk, Clare and Crutchfield, Amanda and Damle, Sagar S and Klein, Stephanie and Swayze, Eric E},
  title = {Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkaf1063}
}
Kostenlos starten →